Recursion Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:RXRX)

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) saw some unusual options trading on Thursday. Investors bought 19,524 call options on the company. This represents an increase of 30% compared to the typical volume of 15,030 call options.

Recursion Pharmaceuticals Stock Up 1.2%

RXRX stock traded up $0.04 during trading on Thursday, hitting $3.08. 19,059,791 shares of the company’s stock were exchanged, compared to its average volume of 17,418,096. The business has a 50-day moving average price of $3.32 and a two-hundred day moving average price of $3.80. The stock has a market capitalization of $1.63 billion, a price-to-earnings ratio of -2.56 and a beta of 1.04. Recursion Pharmaceuticals has a 52-week low of $2.77 and a 52-week high of $7.18. The company has a current ratio of 5.47, a quick ratio of 5.47 and a debt-to-equity ratio of 0.01.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its earnings results on Wednesday, May 6th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.08. The firm had revenue of $6.47 million during the quarter, compared to analysts’ expectations of $15.78 million. Recursion Pharmaceuticals had a negative return on equity of 54.33% and a negative net margin of 842.95%.The firm’s revenue was down 56.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.50) earnings per share. As a group, equities research analysts expect that Recursion Pharmaceuticals will post -0.99 EPS for the current year.

Insider Activity at Recursion Pharmaceuticals

In related news, CFO Ben R. Taylor sold 7,956 shares of the firm’s stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $3.39, for a total transaction of $26,970.84. Following the completion of the transaction, the chief financial officer directly owned 1,180,318 shares in the company, valued at $4,001,278.02. This trade represents a 0.67% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Blake Borgeson sold 30,000 shares of the firm’s stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $3.68, for a total value of $110,400.00. Following the transaction, the director owned 6,169,863 shares of the company’s stock, valued at $22,705,095.84. This trade represents a 0.48% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 125,930 shares of company stock worth $435,942 in the last three months. 8.43% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its holdings in Recursion Pharmaceuticals by 18.6% during the fourth quarter. Vanguard Group Inc. now owns 47,187,759 shares of the company’s stock worth $192,998,000 after acquiring an additional 7,407,606 shares during the period. State Street Corp grew its holdings in Recursion Pharmaceuticals by 38.7% during the fourth quarter. State Street Corp now owns 25,333,888 shares of the company’s stock worth $103,616,000 after acquiring an additional 7,064,963 shares during the period. Norges Bank acquired a new position in Recursion Pharmaceuticals during the fourth quarter worth $23,473,000. ARK Investment Management LLC grew its holdings in Recursion Pharmaceuticals by 11.2% during the fourth quarter. ARK Investment Management LLC now owns 37,316,856 shares of the company’s stock worth $152,626,000 after acquiring an additional 3,771,357 shares during the period. Finally, Renaissance Technologies LLC purchased a new stake in Recursion Pharmaceuticals during the first quarter worth $7,370,000. Institutional investors and hedge funds own 89.06% of the company’s stock.

Analyst Ratings Changes

RXRX has been the subject of a number of research analyst reports. Morgan Stanley raised their target price on Recursion Pharmaceuticals from $5.00 to $5.50 and gave the company an “equal weight” rating in a report on Thursday, May 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Tuesday, April 21st. JPMorgan Chase & Co. decreased their price objective on Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating for the company in a research note on Thursday, April 30th. Wall Street Zen cut Recursion Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, March 28th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $8.00 price objective on shares of Recursion Pharmaceuticals in a research note on Thursday, May 7th. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Recursion Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $8.10.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.